• If you are wondering whether Prestige Consumer Healthcare is attractively priced or just a value trap, the stock's recent performance and fundamentals give you plenty to weigh up.
• The share price recently closed at US$54.59, with returns of a 3.1% decline over 7 days, a 1.9% decline over 30 days, a 10.8% decline year to date, and a 37.3% decline over the last year, while the 3 year and 5 year returns stand at a 6.4% decline and 12.3% respectively.
• Recent coverage has focused on Prestige Consumer Healthcare as a consumer health products company listed on the NYSE, with investors paying close attention to how its portfolio positions it within the broader pharmaceuticals and biotech space. That context has kept valuation in focus as the stock's weaker recent returns have raised questions about whether the current price reflects the underlying business.
• On Simply Wall St's 6 point valuation checklist, Prestige Consumer Healthcare scores 5 out of 6, and the rest of this article will walk through those valuation approaches while also pointing to a deeper way to think about what the stock might be worth by the end.

Approach 1: Prestige Consumer Healthcare Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model estimates what a stock could be worth today by projecting future cash flows and discounting them back to a present value. In this case, the model used is a 2 Stage Free Cash Flow to Equity approach.

Prestige Consumer Healthcare's latest reported free cash flow is about $268 million. Analyst and extrapolated projections used in the model show annual free cash flow figures in the mid $200 million range over the coming years, reaching $330 million in 2031 and then continuing with gradual increases based on estimated growth rates.

Using these projected cash flows, Simply Wall St calculates an intrinsic value of about $163.19 per share. Compared with the recent share price of $54.59, the DCF output suggests the stock trades at a 66.5% discount to this estimate. This points to a materially undervalued reading on this model.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Prestige Consumer Healthcare is undervalued by 66.5%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: Prestige Consumer Healthcare Price vs Earnings

For a profitable company, the P/E ratio is a straightforward way to think about what you are paying for each dollar of earnings. Investors usually accept a higher or lower P/E depending on what they expect for future earnings growth and how risky they believe those earnings are.

Prestige Consumer Healthcare currently trades on a P/E of 13.85x. This sits below the Pharmaceuticals industry average P/E of about 16.05x and the peer group average of 24.17x, which suggests the stock is priced more conservatively than many comparable companies.

Simply Wall St also calculates a proprietary “Fair Ratio” of 13.67x for Prestige Consumer Healthcare. This metric aims to capture a more tailored view of what the P/E might be given factors such as the company’s earnings growth profile, profit margins, industry, market capitalization and risk characteristics. Because it is built on these company specific inputs, it can be more informative than a simple comparison with broad industry or peer averages.

With the current P/E of 13.85x sitting very close to the Fair Ratio of 13.67x, the stock’s valuation on this metric looks broadly aligned with what those fundamentals suggest.

Result: ABOUT RIGHT

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Prestige Consumer Healthcare Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you turn your view of Prestige Consumer Healthcare into a clear story that links what you think about its brands, M&A discipline, supply chain plans, e-commerce progress and margin outlook to a set of revenue, earnings and margin forecasts. These then translate into a Fair Value you can compare with the current price on the Community page, update automatically when new earnings or news arrive, and show how your view sits between more optimistic users who might assume something closer to the US$86.00 high analyst target and more cautious users who lean toward the US$66.00 low target. This can help you decide whether the stock looks more interesting or less interesting for your portfolio.

Do you think there's more to the story for Prestige Consumer Healthcare? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.